23
Fri, Jun
16 New Articles

Eurofins expands its leadership in biopharmaceutical services with the acquisition of Alphora Research Inc

Industry Reports
Typography

Eurofins Scientific , a world leader in biopharmaceutical testing, announces the acquisition of Alphora Research Inc , a full service contract research, development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs), based in Mississauga, Ontario, Canada.    

Alphora has extensive capabilities in multi-step syntheses, as well as the development of cytotoxic and highly potent APIs. It operates two fully integrated facilities to address a wide array of API challenges, providing a full spectrum of complex API development, testing and manufacturing services. As such the company supports biopharmaceutical companies from the preclinical phase through to commercialization of niche products, and is an ideal complement to Eurofins’ discovery and other biopharmaceutical testing activities. Alphora has grown rapidly since it was founded in 2003, and expects to generate revenues in excess of CAD 30m in 2017, with organic growth and EBITDA margin well above Eurofins’ objectives.

Alphora’s expertise in API development, testing and manufacturing provides Eurofins entry into the dynamic and growing CRDMO market. It is uniquely positioned to capitalize on the strong growth and positive trends in the API industry, which are driven by the increasing importance of outsourcing in biopharmaceutical R&D, limited API manufacturing capacity in North America, and increased funding for early stage discovery and development. Furthermore, Alphora is ideally positioned to support the development of discovery candidates that emerge from Eurofins’ extensive drug discovery platform. In addition to Eurofins’ existing capabilities in preclinical, clinical, and GMP product testing, this acquisition of Alphora further strengthens the Group’s highly compelling and integrated offering to enable clients to progress through the entire drug development process.   

Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to welcome Alphora to the Eurofins Group. Alphora’s competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market. We look forward to strengthening their portfolio and operating footprint by providing access to the full range of services and capabilities of the Group.”  

For more information, please visit www.eurofins.com

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 28,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

Market Movers

Rogers Corporation Common Stock

NYQ : ROG - 22 Jun, 3:42pm
106.89
-0.70 (-0.65%) After Hours:
Open 108.05 Mktcap 1.94B
High 108.30 52wk Hight 113.26
Low 105.63 52wk Low 51.98
Vol 67119 Avg Vol 125494
Eps 5.33 P/e 32.34
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 22 Jun, 3:43pm
6.535
-0.005 (-0.076%) After Hours:
Open 6.530 Mktcap 95.28B
High 6.570 52wk Hight 6.990
Low 6.495 52wk Low 3.600
Vol 3.74M Avg Vol 8.67M
Eps 0.490 P/e 13.904
Currency: USD

Merck & Company, Inc. Common St

NYQ : MRK - 22 Jun, 3:43pm
66.07
+0.61 (+0.93%) After Hours:
Open 65.51 Mktcap 180.71B
High 66.37 52wk Hight 66.80
Low 65.38 52wk Low 55.10
Vol 8.19M Avg Vol 8.87M
Eps 3.84 P/e 42.11
Currency: USD

Johnson & Johnson Common Stock

NYQ : JNJ - 22 Jun, 3:43pm
136.19
+1.28 (+0.95%) After Hours:
Open 135.45 Mktcap 366.87B
High 137.00 52wk Hight 137.00
Low 135.27 52wk Low 109.32
Vol 4.85M Avg Vol 5.78M
Eps 7.10 P/e 22.89
Currency: USD

Pfizer, Inc. Common Stock

NYQ : PFE - 22 Jun, 3:43pm
34.10
+0.22 (+0.65%) After Hours:
Open 33.95 Mktcap 203.50B
High 34.48 52wk Hight 37.39
Low 33.92 52wk Low 29.83
Vol 16.64M Avg Vol 21.73M
Eps 2.55 P/e 28.70
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 22 Jun, 12:31pm
13.69
-0.02 (-0.15%) After Hours:
Open 13.72 Mktcap
High 13.72 52wk Hight 16.29
Low 13.69 52wk Low 12.60
Vol 1294 Avg Vol 7128
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.
captcha